BIO, Allergan and Roche call for FDA flexibility with patient experience data
Industry group BIO and biopharma companies Allergan and Roche are calling for the FDA to be flexible in its approach for using patient experience data …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
